Article
Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
European journal of clinical pharmacology - 1 Jan 1994
Botsch S, Heinkele G, Meese C O, Eichelbaum M, Kroemer H K
Abstract excerpt
Metabolism of the antiarrhythmic, propafenone, cosegregates with the sparteine/debrisoquine polymorphism. Patients devoid of CYP2D6 activity have a higher incidence of adverse effects than those with normal enzyme function. In this paper we present a method for rapid assignment of CYP2D6 phenotype using urinary excretion of intact glucuronides of propafenone (PPFG). After establishing an HPLC assay, urinary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.